[{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"||GEF-H1","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"Seed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ST-00937","moa":"RBM39","graph1":"Oncology","graph2":"IND Enabling","graph3":"Seed Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Seed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ST-01156","moa":"RBM39","graph1":"Oncology","graph2":"Phase I","graph3":"Seed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Seed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ST-01156","moa":"RBM39","graph1":"Oncology","graph2":"Phase I","graph3":"Seed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Seed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Covance | Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Plinabulin","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Covance | Icon Plc","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Covance | Icon Plc"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Plinabulin","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Plinabulin","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ BeyondSpring","highestDevelopmentStatusID":"8","companyTruncated":"BeyondSpring \/ BeyondSpring"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BPI-002","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"Seed Therapeutics","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Seed Therapeutics","amount2":1.5,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":1.5,"dosageForm":"Undisclosed","sponsorNew":"Seed Therapeutics \/ Eisai","highestDevelopmentStatusID":"2","companyTruncated":"Seed Therapeutics \/ Eisai"},{"orgOrder":0,"company":"Seed Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Seed Therapeutics","amount2":0.80000000000000004,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.80000000000000004,"dosageForm":"Undisclosed","sponsorNew":"Seed Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Seed Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Seed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"ST-01156","moa":"RBM39","graph1":"Oncology","graph2":"IND Enabling","graph3":"Seed Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Seed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Seed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ST-01156","moa":"RBM39","graph1":"Oncology","graph2":"Phase I","graph3":"Seed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Seed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Salma Sabbour","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeyondSpring \/ Salma Sabbour","highestDevelopmentStatusID":"7","companyTruncated":"BeyondSpring \/ Salma Sabbour"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Lyudmila Bazhenova, M.D.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeyondSpring \/ Lyudmila Bazhenova, M.D.","highestDevelopmentStatusID":"6","companyTruncated":"BeyondSpring \/ Lyudmila Bazhenova, M.D."}]
Find Clinical Drug Pipeline Developments & Deals by BeyondSpring
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
